Top Key Companies for Oncology Drugs (Oral) Market: Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche Ltd, AbbVie Inc, Merck & Co., Inc, AstraZeneca PLC, Amgen, Pfizer Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company.
Global Oncology Drugs (Oral) Market Research Report: 2025-2032 Outlook with Market Insights, Industry and Competitive Analysis Included. Remarkable growth trajectory projected.
Global Oncology Drugs (Oral) Market Overview And Scope:
The Global Oncology Drugs (Oral) Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Oncology Drugs (Oral) utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global Oncology Drugs (Oral) Market Segmentation
By Type, Oncology Drugs (Oral) market has been segmented into:
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers
By Application, Oncology Drugs (Oral) market has been segmented into:
Hospital Pharmacies
Retail Pharmacies/Drug Stores
Others
Regional Analysis of Oncology Drugs (Oral) Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Oncology Drugs (Oral) Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oncology Drugs (Oral) market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Oncology Drugs (Oral) market.
Top Key Companies Covered in Oncology Drugs (Oral) market are:
Johnson & Johnson
Novartis AG
F. Hoffmann-La Roche Ltd
AbbVie Inc
Merck & Co.
Inc
AstraZeneca PLC
Amgen
Pfizer Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
Key Questions answered in the Oncology Drugs (Oral) Market Report:
1. What is the expected Oncology Drugs (Oral) Market size during the forecast period, 2025-2032?
2. Which region is the largest market for the Oncology Drugs (Oral) Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the Oncology Drugs (Oral) Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the Oncology Drugs (Oral) Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key Oncology Drugs (Oral) companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the Oncology Drugs (Oral) Markets?
7. How is the funding and investment landscape in the Oncology Drugs (Oral) Market?
8. Which are the leading consortiums and associations in the Oncology Drugs (Oral) Market, and what is their role in the market?
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Oncology Drugs (Oral) Market by Type
5.1 Oncology Drugs (Oral) Market Overview Snapshot and Growth Engine
5.2 Oncology Drugs (Oral) Market Overview
5.3 Lung Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Lung Cancer: Geographic Segmentation
5.4 Stomach Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Stomach Cancer: Geographic Segmentation
5.5 Colorectal Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Colorectal Cancer: Geographic Segmentation
5.6 Breast Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Breast Cancer: Geographic Segmentation
5.7 Prostate Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Prostate Cancer: Geographic Segmentation
5.8 Liver Cancer
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Liver Cancer: Geographic Segmentation
5.9 Esophagus Cancer
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Esophagus Cancer: Geographic Segmentation
5.10 Cervical Cancer
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size (2017-2032F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 Cervical Cancer: Geographic Segmentation
5.11 Kidney Cancer
5.11.1 Introduction and Market Overview
5.11.2 Historic and Forecasted Market Size (2017-2032F)
5.11.3 Key Market Trends, Growth Factors and Opportunities
5.11.4 Kidney Cancer: Geographic Segmentation
5.12 Bladder Cancer
5.12.1 Introduction and Market Overview
5.12.2 Historic and Forecasted Market Size (2017-2032F)
5.12.3 Key Market Trends, Growth Factors and Opportunities
5.12.4 Bladder Cancer: Geographic Segmentation
5.13 Other Cancers
5.13.1 Introduction and Market Overview
5.13.2 Historic and Forecasted Market Size (2017-2032F)
5.13.3 Key Market Trends, Growth Factors and Opportunities
5.13.4 Other Cancers: Geographic Segmentation
Chapter 6: Oncology Drugs (Oral) Market by Application
6.1 Oncology Drugs (Oral) Market Overview Snapshot and Growth Engine
6.2 Oncology Drugs (Oral) Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies: Geographic Segmentation
6.4 Retail Pharmacies/Drug Stores
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail Pharmacies/Drug Stores: Geographic Segmentation
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Oncology Drugs (Oral) Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Oncology Drugs (Oral) Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Oncology Drugs (Oral) Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 JOHNSON & JOHNSON
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 NOVARTIS AG
7.4 F. HOFFMANN-LA ROCHE LTD
7.5 ABBVIE INC
7.6 MERCK & CO.
7.7 INC
7.8 ASTRAZENECA PLC
7.9 AMGEN
7.10 PFIZER INC
7.11 ASTELLAS PHARMA INC
7.12 BRISTOL-MYERS SQUIBB COMPANY
Chapter 8: Global Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Lung Cancer
8.2.2 Stomach Cancer
8.2.3 Colorectal Cancer
8.2.4 Breast Cancer
8.2.5 Prostate Cancer
8.2.6 Liver Cancer
8.2.7 Esophagus Cancer
8.2.8 Cervical Cancer
8.2.9 Kidney Cancer
8.2.10 Bladder Cancer
8.2.11 Other Cancers
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital Pharmacies
8.3.2 Retail Pharmacies/Drug Stores
8.3.3 Others
Chapter 9: North America Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Lung Cancer
9.4.2 Stomach Cancer
9.4.3 Colorectal Cancer
9.4.4 Breast Cancer
9.4.5 Prostate Cancer
9.4.6 Liver Cancer
9.4.7 Esophagus Cancer
9.4.8 Cervical Cancer
9.4.9 Kidney Cancer
9.4.10 Bladder Cancer
9.4.11 Other Cancers
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital Pharmacies
9.5.2 Retail Pharmacies/Drug Stores
9.5.3 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Lung Cancer
10.4.2 Stomach Cancer
10.4.3 Colorectal Cancer
10.4.4 Breast Cancer
10.4.5 Prostate Cancer
10.4.6 Liver Cancer
10.4.7 Esophagus Cancer
10.4.8 Cervical Cancer
10.4.9 Kidney Cancer
10.4.10 Bladder Cancer
10.4.11 Other Cancers
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital Pharmacies
10.5.2 Retail Pharmacies/Drug Stores
10.5.3 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Lung Cancer
11.4.2 Stomach Cancer
11.4.3 Colorectal Cancer
11.4.4 Breast Cancer
11.4.5 Prostate Cancer
11.4.6 Liver Cancer
11.4.7 Esophagus Cancer
11.4.8 Cervical Cancer
11.4.9 Kidney Cancer
11.4.10 Bladder Cancer
11.4.11 Other Cancers
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital Pharmacies
11.5.2 Retail Pharmacies/Drug Stores
11.5.3 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Lung Cancer
12.4.2 Stomach Cancer
12.4.3 Colorectal Cancer
12.4.4 Breast Cancer
12.4.5 Prostate Cancer
12.4.6 Liver Cancer
12.4.7 Esophagus Cancer
12.4.8 Cervical Cancer
12.4.9 Kidney Cancer
12.4.10 Bladder Cancer
12.4.11 Other Cancers
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital Pharmacies
12.5.2 Retail Pharmacies/Drug Stores
12.5.3 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Lung Cancer
13.4.2 Stomach Cancer
13.4.3 Colorectal Cancer
13.4.4 Breast Cancer
13.4.5 Prostate Cancer
13.4.6 Liver Cancer
13.4.7 Esophagus Cancer
13.4.8 Cervical Cancer
13.4.9 Kidney Cancer
13.4.10 Bladder Cancer
13.4.11 Other Cancers
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital Pharmacies
13.5.2 Retail Pharmacies/Drug Stores
13.5.3 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Oncology Drugs (Oral) Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Lung Cancer
14.4.2 Stomach Cancer
14.4.3 Colorectal Cancer
14.4.4 Breast Cancer
14.4.5 Prostate Cancer
14.4.6 Liver Cancer
14.4.7 Esophagus Cancer
14.4.8 Cervical Cancer
14.4.9 Kidney Cancer
14.4.10 Bladder Cancer
14.4.11 Other Cancers
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospital Pharmacies
14.5.2 Retail Pharmacies/Drug Stores
14.5.3 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Oncology Drugs (Oral) Scope:
|
Report Data
|
Oncology Drugs (Oral) Market
|
|
Oncology Drugs (Oral) Market Size in 2025
|
USD XX million
|
|
Oncology Drugs (Oral) CAGR 2025 - 2032
|
XX%
|
|
Oncology Drugs (Oral) Base Year
|
2024
|
|
Oncology Drugs (Oral) Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche Ltd, AbbVie Inc, Merck & Co., Inc, AstraZeneca PLC, Amgen, Pfizer Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company.
|
|
Key Segments
|
By Type
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers
By Applications
Hospital Pharmacies
Retail Pharmacies/Drug Stores
Others
|
